What are the recommended adult dosing regimens for metoprolol (immediate‑release tartrate and extended‑release succinate) for hypertension, chronic stable angina, acute myocardial infarction, supraventricular tachycardia, heart failure with reduced ejection fraction, and post‑myocardial infarction secondary prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Metoprolol Dosing Table

Hypertension

Metoprolol Tartrate (Immediate-Release)

  • Initial dose: 25–50 mg twice daily 1
  • Maintenance: 100–200 mg daily (divided into two doses) 1
  • Maximum: 200 mg twice daily (400 mg total daily) 1
  • Titration interval: Every 1–2 weeks based on blood pressure response 1

Metoprolol Succinate (Extended-Release)

  • Initial dose: 50 mg once daily 1
  • Maintenance: 50–200 mg once daily 1
  • Maximum: 400 mg once daily 1
  • Titration interval: Every 1–2 weeks based on blood pressure response 1

Chronic Stable Angina

Metoprolol Succinate (Extended-Release)

  • Initial dose: 50–100 mg once daily 1
  • Target dose: 200 mg once daily 1
  • Maximum: 400 mg once daily 1
  • Titration: Gradually increase every 1–2 weeks as tolerated 1

Acute Myocardial Infarction

Intravenous Phase (Early Administration)

  • Initial IV dose: 5 mg slow IV bolus over 1–2 minutes 1
  • Repeat: 5 mg IV every 5 minutes as needed 1
  • Maximum total IV dose: 15 mg (three 5 mg boluses) 1

Critical contraindications before IV administration: Signs of heart failure, low output state, systolic BP <120 mmHg, heart rate >110 bpm or <60 bpm, PR interval >0.24 seconds, second or third-degree heart block, active asthma, age >70 years with risk factors for cardiogenic shock 1

Transition to Oral Therapy

  • Begin oral metoprolol tartrate 15 minutes after last IV dose 1
  • Initial oral dose: 25–50 mg every 6 hours for 48 hours 1
  • Maintenance: Transition to 100 mg twice daily after initial 48-hour period 1

Long-Term Secondary Prevention (Post-MI)

  • Metoprolol succinate 200 mg once daily is the target dose for secondary prevention 1
  • Initial dose: 12.5–25 mg once daily, titrated gradually every 2 weeks 1

Supraventricular Tachycardia (Including Atrial Fibrillation)

Intravenous Administration

  • Initial dose: 5 mg IV over 1–2 minutes 1
  • Repeat: Every 5 minutes as required based on heart rate and blood pressure 1
  • Maximum total dose: 15 mg 1

Oral Maintenance (Atrial Fibrillation Rate Control)

  • Metoprolol tartrate: 25–100 mg twice daily 1
  • Metoprolol succinate: 50–400 mg once daily 1
  • Target resting heart rate: 50–80 bpm (strict control) or <110 bpm (lenient control) 1

Heart Failure with Reduced Ejection Fraction (HFrEF)

Metoprolol Succinate (Extended-Release) – ONLY Evidence-Based Formulation

  • Initial dose: 12.5–25 mg once daily 1
  • Titration: Double the dose every 2 weeks if well tolerated 1
  • Target dose: 200 mg once daily 2, 1
  • Mean effective dose in trials: 159 mg daily 1

Critical principle: Metoprolol tartrate (immediate-release) has never demonstrated mortality benefit in heart failure trials and must not be used as a substitute for metoprolol succinate 2. Only metoprolol succinate 200 mg once daily has proven mortality reduction in heart failure 2.

Monitoring During Titration

  • Monitor at each visit: Heart rate, blood pressure, signs of worsening heart failure 1
  • Target resting heart rate: 50–60 bpm unless limiting side effects occur 1
  • If symptoms worsen: Increase diuretics or ACE inhibitors before reducing beta-blocker dose 2

Post-Myocardial Infarction Secondary Prevention

Metoprolol Succinate (Extended-Release)

  • Initial dose: 12.5–25 mg once daily 1
  • Target dose: 200 mg once daily 1
  • Titration: Gradually increase every 2 weeks to reach target 1

Special Populations & Dosing Considerations

Women

  • Women may achieve optimal outcomes at 50% of guideline-recommended doses due to 50–80% higher metoprolol exposure compared to men 1
  • Consider starting at lower doses (e.g., 12.5 mg) and titrating more cautiously 1

Elderly Patients

  • Start at the lowest recommended dose (12.5–25 mg) 1
  • Titrate more slowly with careful monitoring for hypotension and bradycardia 1

Absolute Contraindications (All Indications)

  • Decompensated heart failure or signs of low cardiac output 1
  • Second or third-degree AV block without functioning pacemaker 1
  • Symptomatic bradycardia (heart rate <50–60 bpm with symptoms) 1
  • Symptomatic hypotension (systolic BP <100 mmHg with symptoms) 1
  • Active asthma or severe reactive airway disease 1
  • Cardiogenic shock 1

Critical Warnings

Never abruptly discontinue metoprolol: Sudden withdrawal can precipitate severe angina, myocardial infarction, ventricular arrhythmias, and a 2.7-fold increased risk of 1-year mortality 1. Always taper gradually over 1–2 weeks by reducing the dose by 25–50% every 1–2 weeks 1.

Formulation matters in heart failure: Only bisoprolol, metoprolol succinate, and carvedilol have proven mortality benefit; beta-blockers cannot be considered interchangeable on a class-effect basis 2.

References

Guideline

Metoprolol Treatment Protocol for Hypertension and Heart-Related Conditions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Converting Metoprolol Succinate to Carvedilol in Chronic Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.